778642-40-3

Upstream product

• 778642-39-0 phenylmethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 106-41-2 4-bromo-phenol 
• 915199-12-1 phenylmethyl 4-[4-(4-piperidinyloxy)phenyl]-1-piperidinecarboxylate 
• 308386-38-1 tert-butyl 4-(4-bromophenoxy) piperidine-1-carboxylate 
• 778642-37-8 phenylmethyl 4-{4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-4-piperidinyl)oxy]phenyl}-4-hydroxy-1-piperidinecarboxylate 
• 915199-13-2 phenylmethyl 4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-1-piperidinecarboxylate 

Downstream Products

• 915199-11-0 1-{[4-(1-azetidinylcarbonyl)phenyl]carbonyl}-4-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)piperidine 

Relevant academic research and scientific papers

SUBSTITUTED PIPERIDINE ANTAGONIST OF HI RECEPTOR TO BE USED FOR THE TREATMENT OF RHINITIS

The present invention relates to the compound, (I) and salts thereof, processes for its preparation, to compositions containing it and to its use in the treatment of various disorders, such as allergic rhinitis.

4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER’S

The present invention provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: R1 represents -C1-6 alkyl-O-C1-6 alkyl, -C3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl and other groups; X represents a bond, O, CO, OCH2, CH2O or SO2; Z represents CO, CONR10 or SO2; R10 represents hydrogen, C1-6 alkyl, -C3-8 cycloalkyl, aryl, heterocyclyl, heteroaryl; A represents a single or a double bond; m and n independently represent 0, 1 or 2; R2 represents hydrogen, C1-6 alkyl or C1-6 alkoxy; R3 represents halogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, cyano, amino, -COC1-6 alkyl, -SO2C1-6 alkyl or trifluoromethyl; R4 represents -(CH2)q-NR11R12 or a group of formula (i) wherein all the other substituents are as defined in claim 1. Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for and are antagonists and/or inverse agonists of the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease.